Table 4.

HR for ICC.

	Cohort				PS matched cohort
	Tenofovir (ref: Entecavir)				Tenofovir (ref: Entecavir)
	HR	95% CI		P-value	HR	95% CI		P-value
Crude model	1.32	0.41	4.30	0.643	0.92	0.28	2.99	0.890
Full model*	1.84	0.54	6.29	0.330	1.04	0.31	3.52	0.954
Main model**	1.67	0.51	5.51	0.397	0.94	0.29	3.07	0.914
IPTW	1.70	0.57	5.02	0.341
Additional covariates
Main model + APRI	1.86	0.56	6.21	0.313	1.03	0.31	3.42	0.961
Main model + FIB4	1.72	0.52	5.69	0.371	0.93	0.29	3.06	0.909
Main model + CTP	1.65	0.50	5.45	0.413	0.94	0.29	3.06	0.912
Main model + AFP	1.67	0.51	5.49	0.401	0.94	0.29	3.07	0.915
Main model + CCI	1.66	0.50	5.48	0.404	0.93	0.28	3.06	0.904
Subgroup analysis***
Sex
Female	3.36	0.21	53.80	0.392	1.47	0.09	24.51	0.787
Male	1.40	0.37	5.35	0.624	0.81	0.21	3.09	0.762
Age, y/o
≤ 50	0.00	0.00		0.997	0.00	0.00		0.997
> 50	2.12	0.61	7.30	0.235	1.24	0.36	4.26	0.733
DM
No	2.08	0.49	8.80	0.319	1.27	0.30	5.35	0.745
Yes	1.03	0.12	9.23	0.980	0.50	0.06	4.52	0.537
Liver cirrhosis
No	0.00	0.00		0.998	0.00	0.00		0.998
Yes	2.00	0.58	6.87	0.271	1.09	0.32	3.74	0.887
Prior NA
No	0.78	0.60	1.01	0.054	0.79	0.60	1.04	0.095
Yes	1.25	0.74	2.11	0.406	1.10	0.61	2.01	0.748
Stratified cDDD
cDDDs ≤ 1095	2.16	0.65	7.19	0.211	1.19	0.36	3.95	0.780
CDDDs > 1095	–	–	–	–	–	–	–	–
CTP score
A	1.71	0.42	6.97	0.455	1.11	0.28	4.48	0.882
B/C	1.60	0.16	15.89	0.688	0.56	0.06	5.49	0.615

PS propensity score, HR hazard ratio, CT confidence interval, IPTW inverse probability treatment weighting, APRI AST to platelet ratio index, FIB-4 fibrosis index based on 4 factors, CTP Child–Turcotte–Pugh, AFP alpha-fetoprotein, CCI Charlson comorbidity index, DM diabetes mellitus.

*Full model is adjusted for age, sex, liver cirrhosis, DM, APRI, FIB4, CCI, CTP, AST, ALT, platelet, AFP, albumin, bilirubin and INR. **Main model is adjusted for age, sex, liver cirrhosis, DM. ***HRs were estimated by fitting the main model.